On March 19, 2025, a delegation led by Wu Haoyu, Deputy Director of the Healthy China Project Management Committee and Chairman of the Advisory Committee of the Central Veteran Cadres Health and Longevity Foundation; Yan Xiaozheng, former Director of the Social Service Department of the Chinese Peasants and Workers Democratic Party Central Committee, Director of the Healthy China Project Management Committee, and Head of the Standardization Expert Group at the National Health Commission’s Science and Technology Institute; Hu Jianhua, former Director of the Talent Bureau of the Central Organization Department; Zhang Hao, Head of the Standardization Expert Group at the National Health Commission’s Science and Technology Institute; and Han Yujun, Deputy Head of the Standardization Expert Group, visited Zhejiang Tianyuan Biotechnology Co., Ltd. (hereinafter referred to as “Tianyuan Biotech”). Company Chairman Huang Bisheng and Group Administrative Director Zhu Youwu accompanied the delegation throughout the visit.

     The delegation first toured Tianyuan Biotech’s Life Science and Technology Exhibition Hall, where they gained a comprehensive understanding of the company’s development journey. From its early exploration in cell and regenerative medicine and genetic testing to its current breakthroughs in technological innovation and industrial applications, every milestone reflects Tianyuan Biotech’s unwavering dedication to advancing life sciences. The hall’s rich displays, cutting-edge scientific models, and dynamic multimedia presentations allowed the leaders to witness firsthand the company’s profound expertise and dynamic progress in the field.

     Subsequently, the two parties held an in-depth development symposium. During the meeting, Chairman Wu Haoyu delivered opening remarks, commending Tianyuan Biotech’s efforts and achievements in advancing the Healthy China initiative. He emphasized that as a leader in life sciences, Tianyuan Biotech has consistently driven innovation, prioritized clinical applications, and achieved remarkable progress in stem cell and regenerative medicine research, injecting fresh vitality into China’s healthcare sector. The company’s development model and scientific accomplishments, he noted, align closely with the national Healthy China strategy and play a pivotal role in improving public health outcomes.

     Director Yan Xiaozheng also delivered a keynote address, highlighting Tianyuan Biotech’s deep expertise and practical experience in stem cell research and genetic testing, which he deemed critical for standardizing the development of China’s health industry. He praised the company’s rigorous quality management practices and innovative approaches, which have set industry benchmarks. Yan urged Tianyuan Biotech to leverage its strengths further, contributing wisdom and momentum to the healthy growth of China’s cell therapy sector.

     Chairman Huang Bisheng extended a warm welcome and heartfelt gratitude to the delegation. He reaffirmed Tianyuan Biotech’s commitment to its founding principles and passion for life sciences. Building on this visit, he pledged to increase R&D investments, deepen industry-academia collaborations, and enhance innovation capabilities. Guided by the Healthy China strategy, Huang vowed to uphold the company’s mission, forge ahead, and make greater contributions to the nation’s life sciences industry and public health.

     The visit by the Healthy China Project Management Committee leaders not only recognized Tianyuan Biotech’s past achievements but also inspired and motivated its future endeavors. With collective support and collaboration, Tianyuan Biotech is poised to achieve even greater milestones in life sciences, bolstering the Healthy China initiative with transformative advancements.